Corporate Governance

Karin Eastham: Director - SGX Pharmaceuticals, Inc.
Karin Eastham

Director
SGX Pharmaceuticals, Inc.
View Video

Ms. Eastham has over 25 years experience in financial and operations management, primarily in life sciences companies. She currently serves as Executive Vice President and Chief Operating Officer, and as a member of the Board of Trustees of the Burnham Institute for Medical Research, a non-profit corporation, engaged in basic biomedical research and the home to three research centers – a Cancer Center, the Del E. Webb Center for Neuroscience and Aging and a Center for research on Infectious and Inflammatory Diseases. From April 1999 to May 2004, Ms. Eastham served as Senior Vice President, Finance, Chief Financial Officer, and Secretary of Diversa Corporation, where she led the company’s IPO, raising over $200 MM. She previously held similar positions with CombiChem, Inc., a computational chemistry company, and Cytel Corporation, a biopharmaceutical company. Ms. Eastham also held several positions, including Vice President, Finance, at Boehringer Mannheim Diagnostics, from 1976 to 1988.

Ms. Eastham serves as a director for several biotechnology companies, including Amylin Pharmaceuticals, Inc., SGX Pharmaceuticals, Inc., and Tercica, Inc., for which she also chairs the audit committees and Illumina, Inc. where she also chairs the compensation committee. She previously served as a director of Molecular Probes, Inc. and Salmedix, Inc., privately-held biotechnology companies, until the sale of the companies to Invitrogen, Inc. and Cephalon, Inc., respectively. Ms. Eastham also serves on the Corporate Directors Forum Board, which focuses on promoting best practices in corporate governance. Ms. Eastham received a B.S. and an M.B.A. from Indiana University and is a Certified Public Accountant and a Certified Director.